

## Flash BioSolutions welcomes Stewart Craig to its esteemed Scientific Advisory Board

Toulouse, France, 30 April 2024 - Flash BioSolutions, a renowned Contract Development and Manufacturing Organization (CDMO) specializing in gene delivery, proudly announces the addition of Stewart Craig to its distinguished Scientific Advisory Board.

With four decades of experience in the biotechnology industry, Stewart Craig brings a wealth of expertise and leadership to his new role. For the past 30 years, Stewart has held executive positions focusing on the strategic development, implementation, and oversight of Chemistry, Manufacturing, and Controls (CMC), Technical Operations and Good Manufacturing Practice (GMP) infrastructures for cutting-edge cell and gene therapy enterprises.

Stewart's journey in biotechnology has been marked by significant contributions to the field as he has played pivotal roles in spearheading the development, manufacturing, and clinical delivery of a diverse portfolio of biologics, including recombinant proteins, antibodies, cell therapies, viral vectors and gene-modified cell products. His expertise extends beyond operational realms, encompassing adept management of regulatory affairs across international jurisdictions, including the US, Canada, Switzerland, and Europe.

As the Co-founder and Principal Consultant at Broken Lance Biotech Consulting, Stewart Craig continues to be a guiding force within the biotech sector. His previous roles as Chief Technical Officer at jCyte, Inc. and Erytech Pharma, along with his tenure as Chief Manufacturing Officer at Orchard Therapeutics Ltd., Chief Operating Officer at Xcytye Therapies, Inc. and Senior Vice President of Technical Operations at Sangamo BioSciences, underscore his invaluable contributions to advancing innovative products into patient treatments.

"We are thrilled to welcome Stewart Craig to our Scientific Advisory Board," expressed **Jérôme Bédier, CEO of Flash BioSolutions**. "His extensive experience and profound understanding of biotechnology will undoubtedly enrich our endeavors as we strive to pioneer transformative treatments for patients worldwide. Stewart's participation will offer invaluable expertise to support the process validation needed to ensure the highest quality standards for our customers, particularly for our LentiCare® and FlashRNA® platforms."

Stewart Craig added: "Joining the Scientific Advisory Board of Flash BioSolutions represents an exciting opportunity for me to contribute to the development of this innovator company within the CDMO sphere. I am deeply convinced that the future of biotechnology lies in dynamic collaborations between key players in the industry. Flash BioSolutions embodies this spirit of innovation and commitment to scientific excellence and quality in gene therapy. I'm driven by the desire to share my expertise and knowledge to help the company reach new heights in the manufacture and development of revolutionary treatments. Together, we can create a significant impact on patients' lives and shape the future of medicine."

As a distinguished member of Flash BioSolutions's Scientific Advisory Board, Stewart Craig will provide invaluable strategic guidance and scientific acumen, further propelling the company's mission to revolutionize gene therapy.

## **About Flash BioSolutions:**

Flash BioSolutions® is a preeminent CDMO specializing in the industrial-scale production of DNA and RNA vectors for clientele within the domains of gene and cell therapy, and vaccine development. Bolstered by a robust manufacturing platform and validated processes honed over two decades, Flash BioSolutions® excels in delivering vectors of unmatched purity and concentration across research, pre-clinical, clinical, and commercial phases.

## **Contact:**

Head of communication Soraya Sandokchi +33 582 955 546 soraya.sandokchi@flashbiosolutions.com